The 36-month beta value for NRIX is at 2.16. Analysts have varying views on the stock, with 10 analysts rating it as a “buy,” 6 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NRIX is 74.71M, and currently, shorts hold a 18.86% of that float. The average trading volume for NRIX on June 19, 2025 was 985.18K shares.
NRIX) stock’s latest price update
Nurix Therapeutics Inc (NASDAQ: NRIX)’s stock price has increased by 2.02 compared to its previous closing price of 11.39. However, the company has seen a -8.00% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-13 that SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on June 10, 2025, the company granted inducement awards to seventeen new employees. The grants were made pursuant to Nurix’s 2024 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).
NRIX’s Market Performance
NRIX’s stock has fallen by -8.00% in the past week, with a monthly rise of 22.19% and a quarterly drop of -16.40%. The volatility ratio for the week is 2.70% while the volatility levels for the last 30 days are 4.04% for Nurix Therapeutics Inc The simple moving average for the last 20 days is 1.48% for NRIX stock, with a simple moving average of -34.85% for the last 200 days.
Analysts’ Opinion of NRIX
Many brokerage firms have already submitted their reports for NRIX stocks, with Leerink Partners repeating the rating for NRIX by listing it as a “Market Perform.” The predicted price for NRIX in the upcoming period, according to Leerink Partners is $16 based on the research report published on March 17, 2025 of the current year 2025.
BTIG Research, on the other hand, stated in their research note that they expect to see NRIX reach a price target of $35. The rating they have provided for NRIX stocks is “Buy” according to the report published on December 10th, 2024.
BMO Capital Markets gave a rating of “Outperform” to NRIX, setting the target price at $35 in the report published on December 06th of the previous year.
NRIX Trading at 8.34% from the 50-Day Moving Average
After a stumble in the market that brought NRIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.69% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NRIX starting from van Houte Hans, who sale 6,198 shares at the price of $11.33 back on May 02 ’25. After this action, van Houte Hans now owns 33,724 shares of Nurix Therapeutics Inc, valued at $70,243 using the latest closing price.
JOHANNES VAN HOUTE, the Officer of Nurix Therapeutics Inc, proposed sale 6,198 shares at $11.16 during a trade that took place back on May 02 ’25, which means that JOHANNES VAN HOUTE is holding shares at $69,170 based on the most recent closing price.
Stock Fundamentals for NRIX
Current profitability levels for the company are sitting at:
- -4.09 for the present operating margin
- 0.78 for the gross margin
The net margin for Nurix Therapeutics Inc stands at -3.69. The total capital return value is set at -0.44. Equity return is now at value -64.16, with -44.93 for asset returns.
Based on Nurix Therapeutics Inc (NRIX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -7.2.
Currently, EBITDA for the company is -196.6 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 14.83. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.26.
Conclusion
In conclusion, Nurix Therapeutics Inc (NRIX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
